As our results revealed that AIMP2-high tumors respond favorably to antiangiogenic therapy, this homogeneous expression pattern may ensure that antiangiogenic therapy may exert a more uniform therapeutic effect, potentially reducing the likelihood of therapy-resistant subpopulations emerging within the tumor. The gene discussed is AIMP2; the disease is neoplasm.